BorchersAT, HagieF, KeenCLet al.The history and contemporary challenges of the US Food and Drug Administration. Clinical Therapeutics, 2007; 29:1–16.
2.
ASGE Technology Committee. Technology status evaluation report. The role of the U.S. Food and Drug Administration in device evaluation and monitoring. Gastrointestinal Endoscopy, 2010; 72:5–10.
3.
TaylorRS, IglesiasCP. Assessing the clinical and cost-effectiveness of medical devices and drugs: Are they that different?Value Health, 2009; 12:404–6.
4.
U.S. Food and Drug Administration. PMA Review Fees. www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevice/PremarketSubmissions/PremarketApprovalPMA/ucm048161.htm. 2011 Nov. 12.
5.
U.S. Department of Health and Human Services, Food and Drug Administration, Center for Devices and Radiological Health, Center for Biologics Evaluation and Research. Draft Guidance for Industry and Food and Drug Administration Staff—Mobile Medical Applications. July21, 2011. www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm263280.htm#1. 2011 Nov. 12.
6.
FDA health app guidance will help some developers, hinder others. Telemedicine and e-Health News Alert, July26, 2011New Rochelle, NY: Mary Ann Liebert.
7.
SchreyöggJ, BäumlerM, BusseR. Balancing adoption and affordability of medical devices in Europe. Health Policy, 2009; 92:218–24.
